Scientific Officer, Executive Director
BioAgilytix
Durham, North Carolina
Lynn Kamen is a Scientific Officer at BioAgilytix. She earned her Ph.D. in Immunology at the University of Michigan and completed a postdoctoral fellowship in immunology at the University of California San Francisco. Lynn has over a decade of experience working in drug development, from early target discovery through clinical development for both large and small molecules at several companies including Portola Pharmaceuticals, and Alector. More recently, Lynn was a principal scientist at Genentech where she supported the in vitro biological characterization of large molecules and lead the development of immunogenicity assays including ADA, NAb and immunogenicity risk ranking assays. She is co-lead of the AAPS NAb working group.
Disclosure information not submitted.
Bioanalytical Approaches for Assessing the Immunogenicity of RNA Therapeutics
Tuesday, July 15, 2025
9:05 AM - 9:35 AM ET
Beyond the Analysis: Immunogenicity and Beyond: Panel Discussion
Tuesday, July 15, 2025
11:05 AM - 11:55 AM ET
Joint Session on the Relationship Between Impurities and Immunogenicity
Thursday, July 17, 2025
8:00 AM - 10:35 AM ET
Joint Session on the Relationship Between Impurities and Immunogenicity: Panel Discussion
Thursday, July 17, 2025
9:35 AM - 10:30 AM ET